Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
20.20
+0.47 (2.38%)
Sep 8, 2026, 4:00 PM EDT - Market closed
Fulgent Genetics Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 323.93 | 322.67 | 283.47 | 289.21 | 618.97 | 992.58 |
Revenue Growth | 6.83% | 13.83% | -1.99% | -53.27% | -37.64% | 135.37% |
Gross Profit Gross Profit Growth | 115.26 | 130.88 | 107.22 | 104.46 | 366.9 | 777.05 |
Operating Income Operating Income Growth | -115.29 | -89.17 | -73.92 | -75.3 | 181.5 | 675.95 |
Net Income Net Income Growth | -84.38 | -60.51 | -42.71 | -167.83 | 143.4 | 507.36 |
Earnings Per Share EPS Growth | -2.81 | -1.97 | -1.41 | -5.63 | 4.63 | 16.38 |
EPS Growth | - | - | - | - | -71.73% | 83.84% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Laboratory Services Laboratory Services Growth | 323.37 | 322.22 | 283.47 | 289.21 | 618.97 | 992.58 |
Therapeutic Development Therapeutic Development Growth | - | 0.45 | - | - | - | - |
Total Total Growth | 323.93 | 322.67 | 283.47 | 289.21 | 618.97 | 992.58 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 551.35 | 705.35 | 828.46 | 847.73 | 852.88 | 935.55 |
Total Debt Total Debt Growth | 9.6 | 8.04 | 9.23 | 16.56 | 38.33 | 30.2 |
Net Cash (Debt) Net Cash Growth | 541.75 | 697.31 | 819.23 | 831.17 | 814.56 | 905.35 |
Net Cash Growth | -29.60% | -14.88% | -1.44% | 2.04% | -10.03% | 117.48% |
Net Cash Per Share Net Cash Per Share Growth | 17.97 | 22.66 | 27.10 | 27.91 | 26.31 | 29.23 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -83.7 | -101.64 | 21.06 | 27 | 253.52 | 538.58 |
Capital Expenditures CapEx Growth | -20.09 | -22.57 | -40.32 | -22.21 | -18.78 | -23.81 |
Free Cash Flow Free Cash Flow Growth | -103.79 | -124.21 | -19.26 | 4.8 | 234.75 | 514.77 |
Free Cash Flow Growth | - | - | - | -97.96% | -54.40% | 387.94% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 35.58% | 40.56% | 37.82% | 36.12% | 59.28% | 78.29% |
Operating Margin | -35.59% | -27.64% | -26.08% | -26.03% | 29.32% | 68.10% |
Pretax Margin | -28.54% | -21.70% | -18.33% | -60.19% | 29.73% | 68.61% |
Profit Margin | -26.05% | -18.75% | -15.07% | -58.03% | 23.17% | 51.12% |
FCF Margin | -32.04% | -38.50% | -6.79% | 1.66% | 37.92% | 51.86% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 6.28 | 5.91 |
Forward PE | - | 247.16 | 247.16 | 247.16 | 247.16 | 13.80 |
P/FCF Ratio | - | - | - | 178.63 | 3.83 | 5.83 |
PS Ratio | 1.72 | 2.52 | 1.99 | 2.96 | 1.45 | 3.02 |